Pfizer bought Global Blood Therapeutics Global Blood Therapeutics from 10/5/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Pfizer completed its acquisition of Global Blood Therapeutics for $5.4, or $68.5 per share.

Global Blood Therapeutics

Review

Source:

{source} pictogram

investors.pfizer.com

Vladimir Petenev

News editor

Write your comment first

News feed

Sovcomflot reported for 6 months of 2024 by RAS

7/30/24 FLOT

QIFA has launched an option program

7/30/24 QIFA

Genetico reported for 6 months of 2024 by RAS

7/30/24 GECO

DIOD reported for 6 months of 2024 by RAS

7/30/24 DIOD

Europlan reported for 6 months of 2024 by RAS

7/30/24 LEAS

Rosseti Kuban reported for 6 months of 2024 by RAS

7/30/24 KUBE

Acron reports for 6 months of 2024 by RAS

7/30/24 AKRN

UAC reports for 6 months of 2024 by RAS

7/30/24 UNAC

Izhstal reported for 6 months of 2024 by RAS

7/30/24 IGST

SFI reported for 6 months of 2024 by RAS

7/30/24 SFIN